NASDAQ · MBIOHealthcarePharmaceuticals

Mustang Bio news

$0.4796−5.39%

Close Sep 29, 2026 · split-adjusted

Articles · 30 days1English, de-duplicated

Positive1100% of coverage

Neutral00%

Negative00% of coverage

About Mustang Bio

No recent articles focused on Mustang Bio.

Also mentions MBIO

Articles that tag MBIO but are mainly about other companies.

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient Demand

GlobeNewswire Inc.Sep 16, 4:55 AM ET▲ Positive

Mustang Bio is developing MB-106, an emerging CAR T candidate in a growing market with expanding indications and earlier treatment line adoption opportunities.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology